Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDominik ChraniukSLSung‐Eun LeeMTMoshe Talpaz

Discussion

Loading...

Member takes

Overview

Double-blind trial found improved hemoglobin and symptom response in myelofibrosis, suggesting better outcomes with pelabresib and ruxolitinib.

Key Points

  • 91.5% achieved spleen volume response in the pelabresib plus ruxolitinib arm compared to 57.5% in placebo at week 96.
  • Hemoglobin response rates were 17.8% versus 11.6%, substantiating better clinical outcomes on pelabresib plus ruxolitinib.
  • Randomized, double-blind Phase III trial indicated low-grade adverse events and similar safety profiles for both treatments.
  • Progression-free survival was numerically better for pelabresib plus ruxolitinib, highlighting possible survival benefits.

Cite This Study

Chraniuk et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de44https://doi.org/10.1182/blood-2025-910
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.2025
  2. 2Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics2025
  3. 3Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial2025 · 1 citations
  4. 4A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks2025 · 1 citations
  5. 5BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study2025 · 1 citations